Breakthrough Data from EADV 2026 Reveals Insight into DecisionDx-Melanoma and Surgical Management Benefits #United_States #Friendswood #Castle_Biosciences #DecisionDx-Melanoma #EADV_2026

Transforming Barrett's Esophagus Management: The TissueCypher® Breakthrough Explained #United_States #Barrett's_Esophagus #Castle_Biosciences #TissueCypher #Friendwood

New Research Underscores Importance of Molecular Testing in Atopic Dermatitis Treatment Choices #None #Atopic_Dermatitis #Castle_Biosciences #AdvanceAD-Tx #Friendwood

New Modeling Study Reveals Improved Care Management for Barrett's Esophagus Patients Using TissueCypher® Test #USA #Friendswood #Barrett's_Esophagus #Castle_Biosciences #TissueCypher

Castle Biosciences Reveal Significant Advancements in Cutaneous Cancer Care with DecisionDx-SCC #USA #Castle_Biosciences #Friendwood #DecisionDx-SCC #Cutaneous_cancer

SciBase Strengthens Partnership with Castle Biosciences Through New Order and Clinical Studies #Sweden #Stockholm #SciBase #Castle_Biosciences #Nevisense_Go

SciBase Strengthens Collaboration with Castle Biosciences Through Additional Order #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

SciBase Strengthens Partnership with Castle Biosciences Through New Order #Sweden #Stockholm #SciBase #Castle_Biosciences #Nevisense_Go